FDA sets review date for Ironshore Pharmaceuticals’ ADHD drug HLD200
Ironshore Pharmaceuticals & Development, a subsidiary of Highland Therapeutics, has reached a significant milestone with the U.S. Food and Drug Administration’s (FDA) acceptance of their resubmitted New Drug Application (NDA) for HLD200, a novel treatment for Attention Deficit Hyperactivity Disorder (ADHD). The FDA has scheduled the Prescription Drug User Fee Act (PDUFA) decision for August […]